La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease

Identifieur interne : 002E91 ( Main/Exploration ); précédent : 002E90; suivant : 002E92

[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease

Auteurs : Ajit Kumar [Canada] ; Sharanpal Mann [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada] ; Chong S. Lee [Canada]

Source :

RBID : Pascal:04-0278162

Descripteurs français

English descriptors

Abstract

Levodopa effectively improves motor symptoms of Parkinson's disease. However, the beneficial effects of levodopa often erode over time with the emergence of response fluctuations. Although these response changes have been recognized from the early levodopa era, their mechanisms remain poorly understood. We investigated the role of dopamine (DA) terminal loss in the development of motor fluctuations by employing PET with [11C](±)dihydrotetrabenazine ([11C]DTBZ) as an in vivo marker for DA nerve terminals. Levodopa response was characterized by analysing the time-response curve to a single dose of levodopa with a finger-tapping test. PET scans were performed in 11 patients with asymmetric Parkinson's disease (age: 61.12 ± 7.97 years; duration of Parkinson's disease: 10.55 ± 4.53 years; mean ± SD). Each patient performed finger-tapping tests for up to 5 h after taking a therapeutic dose of levodopa. Results showed significantly lower [11C]DTBZ binding potential (BP; Bmax/Kd) and baseline tapping rates on the more affected putamen and corresponding body side, respectively, than on the other (P = 0.003 for the former, P = 0.013 for the latter). Among the variables describing the time-response curve, the duration and early decay time were significantly shorter on the more affected side (P = 0.051 and P = 0.021, respectively). Latency to the onset and latency to 50% Emax (the magnitude of the levodopa response) were significantly longer on the more-affected side (P = 0.013 and P = 0.004, respectively). Emax was not significantly different between the two sides. The asymmetry (difference from the more affected to less affected side) of [11C]DTBZ BP in the putamen showed a highly significant correlation with the corresponding asymmetry of the estimated EC50 (levodopa concentration producing 50% of the maximal response; P = 0.022; r = -0.727), a marginally significant correlation with that of latency to the onset (P = 0.065; r = -0.583) and no significant correlation with that of the magnitude, duration or early decay time. This pattern of changes in levodopa response from the less affected to more affected side was similar to that from stable to fluctuating responders except for the latency to onset. These findings suggest a pathogenetic role for DA terminal loss in the development of motor fluctuations. However, the absence of a significant correlation between the early decay of levodopa response and DA terminal density suggests that DA terminal loss alone cannot account for the development of motor fluctuations. Therefore, our study suggests that both levodopa treatment and DA terminal loss contribute to the pathogenesis of motor fluctuations.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">[
<sup>11</sup>
C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease</title>
<author>
<name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mann, Sharanpal" sort="Mann, Sharanpal" uniqKey="Mann S" first="Sharanpal" last="Mann">Sharanpal Mann</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Departments of Physics and Astronomy, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lee, Chong S" sort="Lee, Chong S" uniqKey="Lee C" first="Chong S." last="Lee">Chong S. Lee</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">04-0278162</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0278162 INIST</idno>
<idno type="RBID">Pascal:04-0278162</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A03</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000320</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000903</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000903</idno>
<idno type="wicri:Area/Main/Merge">003289</idno>
<idno type="wicri:Area/Main/Curation">002E91</idno>
<idno type="wicri:Area/Main/Exploration">002E91</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">[
<sup>11</sup>
C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease</title>
<author>
<name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mann, Sharanpal" sort="Mann, Sharanpal" uniqKey="Mann S" first="Sharanpal" last="Mann">Sharanpal Mann</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Departments of Physics and Astronomy, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>TRIUMF, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lee, Chong S" sort="Lee, Chong S" uniqKey="Lee C" first="Chong S." last="Lee">Chong S. Lee</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
<imprint>
<date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Dopamine</term>
<term>Emergence</term>
<term>Emission tomography</term>
<term>Finger</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Levodopa</term>
<term>Levodopa test</term>
<term>Magnitude</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Positron</term>
<term>Putamen</term>
<term>Rate</term>
<term>Single dose</term>
<term>Tapping</term>
<term>Tapping Test</term>
<term>Time response</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Positon</term>
<term>Tomoscintigraphie</term>
<term>Système nerveux pathologie</term>
<term>Lévodopa</term>
<term>Réponse temporelle</term>
<term>Emergence</term>
<term>Fluctuation</term>
<term>Dopamine</term>
<term>Dose unique</term>
<term>Test lévodopa</term>
<term>Doigt</term>
<term>Tapping Test</term>
<term>Homme</term>
<term>Traitement</term>
<term>Taraudage</term>
<term>Taux</term>
<term>Putamen</term>
<term>Magnitude</term>
<term>Pathogénie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Levodopa effectively improves motor symptoms of Parkinson's disease. However, the beneficial effects of levodopa often erode over time with the emergence of response fluctuations. Although these response changes have been recognized from the early levodopa era, their mechanisms remain poorly understood. We investigated the role of dopamine (DA) terminal loss in the development of motor fluctuations by employing PET with [
<sup>11</sup>
C](±)dihydrotetrabenazine ([
<sup>11</sup>
C]DTBZ) as an in vivo marker for DA nerve terminals. Levodopa response was characterized by analysing the time-response curve to a single dose of levodopa with a finger-tapping test. PET scans were performed in 11 patients with asymmetric Parkinson's disease (age: 61.12 ± 7.97 years; duration of Parkinson's disease: 10.55 ± 4.53 years; mean ± SD). Each patient performed finger-tapping tests for up to 5 h after taking a therapeutic dose of levodopa. Results showed significantly lower [
<sup>11</sup>
C]DTBZ binding potential (BP; B
<sub>max</sub>
/K
<sub>d</sub>
) and baseline tapping rates on the more affected putamen and corresponding body side, respectively, than on the other (P = 0.003 for the former, P = 0.013 for the latter). Among the variables describing the time-response curve, the duration and early decay time were significantly shorter on the more affected side (P = 0.051 and P = 0.021, respectively). Latency to the onset and latency to 50% E
<sub>max</sub>
(the magnitude of the levodopa response) were significantly longer on the more-affected side (P = 0.013 and P = 0.004, respectively). E
<sub>max</sub>
was not significantly different between the two sides. The asymmetry (difference from the more affected to less affected side) of [
<sup>11</sup>
C]DTBZ BP in the putamen showed a highly significant correlation with the corresponding asymmetry of the estimated EC
<sub>50</sub>
(levodopa concentration producing 50% of the maximal response; P = 0.022; r = -0.727), a marginally significant correlation with that of latency to the onset (P = 0.065; r = -0.583) and no significant correlation with that of the magnitude, duration or early decay time. This pattern of changes in levodopa response from the less affected to more affected side was similar to that from stable to fluctuating responders except for the latency to onset. These findings suggest a pathogenetic role for DA terminal loss in the development of motor fluctuations. However, the absence of a significant correlation between the early decay of levodopa response and DA terminal density suggests that DA terminal loss alone cannot account for the development of motor fluctuations. Therefore, our study suggests that both levodopa treatment and DA terminal loss contribute to the pathogenesis of motor fluctuations.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<country name="Canada">
<noRegion>
<name sortKey="Kumar, Ajit" sort="Kumar, Ajit" uniqKey="Kumar A" first="Ajit" last="Kumar">Ajit Kumar</name>
</noRegion>
<name sortKey="Lee, Chong S" sort="Lee, Chong S" uniqKey="Lee C" first="Chong S." last="Lee">Chong S. Lee</name>
<name sortKey="Mann, Sharanpal" sort="Mann, Sharanpal" uniqKey="Mann S" first="Sharanpal" last="Mann">Sharanpal Mann</name>
<name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E91 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E91 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0278162
   |texte=   [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022